A dose-response study of alprostadil in patients with erectile dysfunction

Gana, Telesforo E.; Quizanos, Luis F.; Castell, Raul; Dator, Jose D.; Gatchalian, Eduardo R.; Lim, Guerilio U.

doi:10.1016/s0011-393x(96)80075-0

Cited by 2 publications

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The dose which appears to optimal agreement between subjects' assessment and Investigators includes having a time of 30±60 min of a full erection as assessed by the physician. Unlike other studies that have reported a correlation between origin of ED and dose response ef®cacy, 18 this study did not ®nd any signi®cant correlations between these factors. When analyzing by country there were no notable differences between Korean and Indonesian men in their minimally effective or optimal dose responses.…”

Section: Discussioncontrasting

confidence: 99%

A dose-response study of alprostadil sterile powder (S.Po.) (Caverject®) for the treatment of erectile dysfunction in Korean and Indonesian men

et al. 1997

View full text Add to dashboard Cite

This open-label, dose-escalation study investigated the ef®cacy and safety of alprostadil (PGE 1 , prostaglandin E 1 ) Sterile Powder (S.Po.) (Caverject # ) for treatment of erectile dysfunction (ED) in 84 men with ED of various etiologies lasting ! 4 months. Doses started with 2.5 mg, then 5 mg, 10, 15, 20, 30, up to a 40 mg maximum. Eligible patients received single alprostadil injections in the physician's of®ce until an erection occurred. Ten minutes after injection, the patient's erection was clinically evaluated. Optimal response was de®ned as erection suf®cient to permit vaginal penetration and lasting 30±60 min. The patient also reported his own evaluation of response and any side effects. Patients were 24±65 y old (mean: 43.7 y), had ED of psychogenic, vascular, or neurogenic origin lasting 4 months±30 y (mean: 3.75 y). Of 84 patients enrolled, 82 completed the study. In the 82 patients who completed the study 78 (92.9%) achieved an optimal response; 18/78 patients (23.1%) had an optimal response at 2.5 mg, 9/78 (11.5%) at 5 mg, 21/78 (26.9%) at 10 mg, 12/ 78 (15.4%) at 15 mg, and 11/78 (14.1%) at 20 mg. Only 5/78 (6.4%) at 30 mg and 2/78 (2.6%) at 40 mg achieved an optimal response. Mean optimal alprostadil dose was 11.9 mg, and the mean minimal effective dose was 9.9 mg. Mean onset of erection was 11.2 min; mean duration of erection was 50.5 min. Penile pain in ®ve patients (6%) was the only reported side effect.

show abstract

Section: Discussioncontrasting

confidence: 99%

A dose-response study of alprostadil sterile powder (S.Po.) (Caverject®) for the treatment of erectile dysfunction in Korean and Indonesian men

et al. 1997

View full text Add to dashboard Cite

show abstract

Safety and Efficacy of Alprostadil Sterile Powder (S. Po., CAVERJECT<sup>®</sup>) in Diabetic Patients with Erectile Dysfunction

Tsai

Lin²,

Lin³

2000

European Urology

View full text Add to dashboard Cite

A dose-response study of alprostadil in patients with erectile dysfunction

Cited by 2 publications

References 11 publications

A dose-response study of alprostadil sterile powder (S.Po.) (Caverject®) for the treatment of erectile dysfunction in Korean and Indonesian men

A dose-response study of alprostadil sterile powder (S.Po.) (Caverject®) for the treatment of erectile dysfunction in Korean and Indonesian men

Safety and Efficacy of Alprostadil Sterile Powder (S. Po., CAVERJECT<sup>®</sup>) in Diabetic Patients with Erectile Dysfunction

Contact Info

Product

Resources

About

A dose-response study of alprostadil in patients with erectile dysfunction

Cited by 2 publications

References 11 publications

A dose-response study of alprostadil sterile powder (S.Po.) (Caverject®) for the treatment of erectile dysfunction in Korean and Indonesian men

A dose-response study of alprostadil sterile powder (S.Po.) (Caverject®) for the treatment of erectile dysfunction in Korean and Indonesian men

Safety and Efficacy of Alprostadil Sterile Powder (S. Po., CAVERJECT<sup>&reg;</sup>) in Diabetic Patients with Erectile Dysfunction

Contact Info

Product

Resources

About

Safety and Efficacy of Alprostadil Sterile Powder (S. Po., CAVERJECT<sup>®</sup>) in Diabetic Patients with Erectile Dysfunction